{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"}]}],"title":"Local control"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":"Abscopal response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"description":"NSCLC: Local control - Having two or more scans with RECIST response of stable disease (SD), one response of SD followed by non-confirmed PR, or a confirmed response of PR.\n\nAbscopal response occurs when a local therapy, such as radiation therapy, not only shrinks the targeted tumor(s) but also leads to the shrinkage of untreated tumors elsewhere in the body. Abscopal response is measured using RECIST criteria (proportion of patients with complete (CR) or partial (PR) response to therapy).","groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG000","title":"Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG001","title":"Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"OG002","title":"Arm C (Tremelimumab, Durvalumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants receiving at least one regimen of protocol therapy.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Local Control Rate and Abscopal Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}